BWXT Medical and NorthStar Medical Radioisotopes Sign Supply Agreement Supporting Actinium-225 Production
BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc. (NYSE: BWXT) and NorthStar Medical Radioisotopes, LLC (NorthStar) today announced that they have signed a Master Services Agreement (MSA), which will facilitate the production of actinium-225 (Ac-225), a critical medical isotope used to kill cancer cells while minimizing the impact to healthy tissues.
BWXT to Evaluate Locations for Building New Nuclear TRISO Fuel Production Facility to Support Advanced Reactor Deployment
(LYNCHBURG, Va. – July 18, 2024) – BWX Technologies, Inc. (NYSE: BWXT) is evaluating locations for a potential new TRISO nuclear fuel production facility to support anticipated future demand for advanced reactor deployment. As part of this effort, BWXT’s Advanced Technologies subsidiary has signed a cooperation agreement with the State of Wyoming to evaluate the requirements for siting a fuel fabrication facility in the state. The roughly 18-month effort will evaluate such matters as potential factory locations, product specifications, facility design and engineering, estimated capital expenditures and operating costs, staffing and worker skill requirements, supply chain necessities, licensing and other requirements.